Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Results from the open-label extension study of PHOTON demonstrate patients with diabetic macular edema (DME) randomized to Eylea 8 mg maintained visual and anatomic improvements at the end of three years
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
We now rank 3rd in pharmaceutical production by volume and 14th by value
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Notes shall not be offered or sold in India
These clinical studies support the interchangeability of adalimumab-fkjp at low-concentration with high-concentration adalimumab and ustekinumab biosimilarity
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
Target identification will commence on 17 September 2024, following the timeline provided in the campaign guidelines
Subscribe To Our Newsletter & Stay Updated
